UK markets closed
  • NIKKEI 225

    29,161.80
    +213.07 (+0.74%)
     
  • HANG SENG

    28,842.13
    +103.23 (+0.36%)
     
  • CRUDE OIL

    70.90
    -0.01 (-0.01%)
     
  • GOLD FUTURES

    1,866.70
    -12.90 (-0.69%)
     
  • DOW

    34,271.03
    -208.57 (-0.60%)
     
  • BTC-GBP

    28,038.38
    +1,399.46 (+5.25%)
     
  • CMC Crypto 200

    988.67
    +19.83 (+2.05%)
     
  • ^IXIC

    14,123.67
    +54.25 (+0.39%)
     
  • ^FTAS

    4,074.57
    +6.24 (+0.15%)
     

Transaction in own shares

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

Arix Bioscience PLC (ARIX)
08-Jun-2021 / 17:14 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc

 

Transaction in own shares

 

LONDON, 08 June 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE:ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it purchased the following number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a buyback programme announced on 22 March 2021.

 

Date of purchase

08 June 2021

Aggregate number of shares purchased

36,000

Highest price paid per share

175.00p

Lowest price paid per share

175.00p

Average price paid per share

175.00p

 

Arix intends to retain the purchased shares in treasury.

Following settlement of the above purchase, Arix will have 131,790,800 ordinary shares of 0.001 pence each in issue (excluding 3,818,853 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.             

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.

[ENDS]

 

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

08/06/2021

14:09:14

36,000

175.00

London Stock Exchange

00245044856TRLO1

 

  


ISIN:

GB00BD045071

Category Code:

POS

TIDM:

ARIX

LEI Code:

213800OVT3AHQCXNIX43

Sequence No.:

110084

EQS News ID:

1205743


 

End of Announcement

EQS News Service

show this
show this